A careful risk/ benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel to patients with pre-existing or recent onset of CNS demyelinating disease, or to those who are considered to have an increased risk of developing demyelinating disease.
Korábbi vagy meglévő központi idegrendszeri demyelinisatiós elváltozásban, ill. azok esetében, akiknek fokozott kockázatuk van demyelinisatiós